4.7 Article

Formulation of Newcastle disease virus coupled calcium phosphate nanoparticles: An effective strategy for oculonasal delivery to chicken

Journal

COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 116, Issue -, Pages 9-16

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2013.12.017

Keywords

Nanoparticle; Calcium phosphate; Immune responses; Virus delivery; Cyclodextrin

Funding

  1. Translational Research Platform for Veterinary Biologicals
  2. TANUVAS
  3. DBT [BT/PR9480/AAQ/01/343/2007]
  4. Department of Biotechnology (DBT), New Delhi

Ask authors/readers for more resources

In this report, calcium phosphate (CaP) nanoparticles were synthesized by continuous flow method using beta-cyclodextrin (beta-CD) as a medium and functionalized with amino propyl triethoxy silane (APTES). The blood biocompatibility of the nanoparticles was assessed using the whole blood haemolysis, erythrocytes haemolysis and erythrocyte aggregation tests. Based on the results, we found that the synthesized beta-CD-CaP nanoparticles did not cause any remarkable toxic effect. The 5-dimethylthiazol-2-yl-2, 5-diphenyltetrazolium bromide (MU) assay of chicken peripheral blood mononucleated cells (PBMCs) incubated with these nanoparticles indicated that these particles did not exert any significant cytotoxicity. The aminosilane functional group modified beta-CD-CaP was used as tool for coupling of Newcastle disease virus (NDV). The NDV conjugated nanoparticles were confirmed by using Fourier transformed infrared spectroscopy, X-ray diffraction patterns, Raman spectroscopy differential scanning calorimetry and energy-dispersive X-ray spectroscopy. lmmunogenicity trials in chickens proved that beta-CD-CaP-NDV used as a vaccine was better than the commercial vaccine when given oculonasally during the first 2 weeks post vaccination. The birds vaccinated with the above nano-NDV vaccine were completely protected against virulent NDV challenge. This study confirms that the oculonasal beta-CD-CaP-NDV delivery of vaccines is a potential method for enhancing the immune responses of existing commercial vaccines. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available